Acurx Pharmaceuticals (ACXP) Competitors $5.25 +0.53 (+11.14%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACXP vs. SNYR, MURA, MAAQ, CASI, TRIB, KZR, JATT, MIRA, RNTX, and TENXShould you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Synergy CHC (SNYR), Mural Oncology (MURA), Mana Capital Acquisition (MAAQ), CASI Pharmaceuticals (CASI), Trinity Biotech (TRIB), Kezar Life Sciences (KZR), JATT Acquisition (JATT), MIRA Pharmaceuticals (MIRA), Rein Therapeutics (RNTX), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceutical products" industry. Acurx Pharmaceuticals vs. Its Competitors Synergy CHC Mural Oncology Mana Capital Acquisition CASI Pharmaceuticals Trinity Biotech Kezar Life Sciences JATT Acquisition MIRA Pharmaceuticals Rein Therapeutics Tenax Therapeutics Synergy CHC (NASDAQ:SNYR) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Is SNYR or ACXP more profitable? Synergy CHC has a net margin of 10.02% compared to Acurx Pharmaceuticals' net margin of 0.00%. Synergy CHC's return on equity of -18.56% beat Acurx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Synergy CHC10.02% -18.56% 20.28% Acurx Pharmaceuticals N/A -436.83%-192.25% Do institutionals & insiders believe in SNYR or ACXP? 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 56.6% of Synergy CHC shares are held by company insiders. Comparatively, 20.3% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend SNYR or ACXP? Synergy CHC currently has a consensus price target of $10.00, indicating a potential upside of 236.70%. Acurx Pharmaceuticals has a consensus price target of $31.00, indicating a potential upside of 490.93%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Synergy CHC.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synergy CHC 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to SNYR or ACXP? In the previous week, Synergy CHC had 3 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Synergy CHC and 1 mentions for Acurx Pharmaceuticals. Synergy CHC's average media sentiment score of 0.01 beat Acurx Pharmaceuticals' score of 0.00 indicating that Synergy CHC is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synergy CHC 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acurx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, SNYR or ACXP? Synergy CHC has higher revenue and earnings than Acurx Pharmaceuticals. Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Synergy CHC, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynergy CHC$33.70M0.83$2.12M$0.387.82Acurx PharmaceuticalsN/AN/A-$14.10M-$10.69-0.49 SummarySynergy CHC beats Acurx Pharmaceuticals on 12 of the 14 factors compared between the two stocks. Get Acurx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACXP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACXP vs. The Competition Export to ExcelMetricAcurx PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.26M$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-0.4921.0030.8325.91Price / SalesN/A392.25469.77121.46Price / CashN/A43.2325.7828.79Price / Book8.339.739.466.03Net Income-$14.10M-$54.08M$3.27B$265.29M7 Day Performance1.86%3.12%2.37%2.86%1 Month Performance-35.38%4.57%3.88%1.23%1 Year Performance-88.44%10.22%30.52%19.11% Acurx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACXPAcurx Pharmaceuticals2.4168 of 5 stars$5.25+11.1%$31.00+490.9%-89.6%$8.26MN/A-0.493SNYRSynergy CHC4.3562 of 5 stars$3.48+1.5%$10.00+187.4%+2,840.0%$31.54M$33.70M9.1640MURAMural Oncology2.9402 of 5 stars$1.82+3.4%$12.00+559.3%-39.9%$30.49MN/A-0.21119MAAQMana Capital AcquisitionN/A$3.63-9.8%N/A+771.9%$29.49MN/A0.001CASICASI Pharmaceuticals3.6973 of 5 stars$2.26-5.0%$4.00+77.0%-63.4%$29.27M$28.54M-0.89180Gap DownTRIBTrinity Biotech1.4457 of 5 stars$1.57-3.1%N/A-21.5%$29.25M$61.56M-0.54480Upcoming EarningsKZRKezar Life Sciences3.6937 of 5 stars$3.86-2.8%$9.00+133.2%-35.4%$29.07M$7M-0.4060High Trading VolumeJATTJATT AcquisitionN/A$1.66-3.5%N/A-43.7%$28.64MN/A0.003High Trading VolumeMIRAMIRA Pharmaceuticals3.0026 of 5 stars$1.48-1.3%$17.00+1,048.6%-22.7%$28.60MN/A-3.022Analyst UpgradeRNTXRein TherapeuticsN/A$1.13-5.4%N/AN/A$27.52MN/A-0.429TENXTenax Therapeutics1.4637 of 5 stars$6.01+0.7%$17.00+182.9%+42.2%$27.24MN/A-6.539 Related Companies and Tools Related Companies Synergy CHC Alternatives Mural Oncology Alternatives Mana Capital Acquisition Alternatives CASI Pharmaceuticals Alternatives Trinity Biotech Alternatives Kezar Life Sciences Alternatives JATT Acquisition Alternatives MIRA Pharmaceuticals Alternatives Rein Therapeutics Alternatives Tenax Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACXP) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access